Casey McDonald

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Rethinking views on limited-efficacy drug approvals may be in order.

Cleveland Clinic looks at the big medical innovations in store for 2017.

The industry is readying for a leap into a new age of complex therapies, as new heights are reached in fields such as regenerative cell-based therapies, CAR-T and immuno-oncology combinations. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality.

Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.

When lobbying tips the scales: a path to drug approval.

Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation

Vice President, US Payer & Institutional Strategy Lead, Shire

Vice President, Business Development, Regeneron Pharmaceuticals

Senior Director, Marketing, XenoPort

Pharm Exec convenes some of the industry’s top business development professionals and negotiators to talk about the current climate for biophamara dealmaking and the critical job of appraising new assets and their potential as market-worthy and transformative products for patients.

In the spirit of the Olympics, we cite some of the feel-good and not-so-good stories making waves in the competitive world of pharma.

Pharm Exec adds up some interesting figures from recent industry news.

As drugmakers seek engagement, patients are buried in content. Thus, quality and appealing material is a must to grab a share of the narrow bandwidths that patients possess.

Patients are buried in content, so it must to grab a share of the narrow bandwidths that they possess, writes Casey McDonald

The World Medical Innovation Forum presents its second list of breakthrough technologies-this time focused on oncology.

Pharm Exec’s 10th annual Brand of the Year is Bristol-Myers Squibb’s Opdivo, which has raced into the lead position in the treatment-shifting immuno-oncology space behind launches in three key cancers-melanoma, lung, and renal.

A new wave of technologies supported by innovative business models is transforming the vaccine landscape - and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.

As Mr Shkreli goes to Washington, Casey McDonald considers what the silver screen treatment of this chapter in the pharma bro saga might be like.

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

Casey McDonald keeps an eye on the one of the healthcare industry’s biggest weeks on Twitter with regular updates here.

January 11, 2016.

January 08, 2016.

Cures remain elusive, but regulators and industry are building ties that bind.

Cleveland Clinic’s Top Medical Innovations for 2016.

The All-Star CEO panel last week’s Forbes Healthcare Summit was overshadowed by Matthew Herper’s interview with industry’s leading villain, Martin Shkreli, showing that drug pricing is still the leading topic on everyone’s minds.

Senior Editor Casey McDonald visits with industry and regulatory officials in Bogotá to discuss colombia’s strategy for growing its life sciences enterprise, and whether it can be a stable force amid the region’s historically challenging macroeconomic and political fluctuations.

Rare disease supporters deliver inspiration and optimism-as well as promise of regulatory cooperation.

Prix Galien USA had its day, a fall tradition bringing the celebs of the biopharma industry to New York City for discussion and debate and a night of glitz. Casey McDonald reports.